Hong Kong – Mainland Chinese medicine expert group of Central Authorities discusses with Western medicine experts on critical paediatric cases and receives briefing on preparation progress of first CM hospital in Hong Kong (with photos)

Mainland Chinese medicine expert group of Central Authorities discusses with Western medicine experts on critical paediatric cases and receives briefing on preparation progress of first CM hospital in Hong Kong (with photos)

******************************************************************************************


     The expert group led by the leader of the Mainland Chinese medicine expert group of the Central Authorities, Mr Tong Xiaolin, continued its visit in Hong Kong on April 4.



     In the morning, the expert group visited Queen Mary Hospital (QMH) to receive briefing from Cluster Chief Executive (Hong Kong West) of the Hospital Authority and Hospital Chief Executive of the QMH and Tsan Yuk Hospital, Dr Theresa Li; Chief of Service of Paediatrics and Adolescent Medicine Department of the QMH, Dr Lee So-lun; Chair Professor of Department of Paediatrics and Adolescent Medicine of The University of Hong Kong, Professor Lau Yu-lung; and the QMH medical team sharing the experience on the treatment for patients infected with COVID-19.



     The QMH medical team and the expert group have had in-depth discussion on some cases, in particular discussed the management of the critical paediatrics cases. The QMH medical team and the expert groups have also shared the experience on Chinese and Western medicine collaboration and the application of Chinese medicine in the management of patients infected with COVID-19 thoroughly.



     In the afternoon, the expert group met with the representatives of the Chinese Medicine Hospital Project Office (CMHPO) of the Food and Health Bureau. The Project Director of the CMHPO, Dr Cheung Wai-lun, introduced to them the positioning, service plan, design concept, operation model and commissioning progress of the first Chinese medicine hospital (CMH) in Hong Kong. They also discussed how to promote the development of the CMH in Hong Kong through training of professionals and development of services.



     Led by Mr Tong, the Mainland Chinese medicine expert group arrived in Hong Kong on March 29 to conduct visits.

Hua Medicine Announces 2021 Annual Results

Hua Medicine (the “Company”, Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the “Reporting Period”). The Reporting Period witnessed significant milestones in the commercialization process of dorzagliatin. The New Drug Application (NDA) of dorzagliatin for the treatment of Type 2 Diabetes was submitted to, and accepted by, the China National Medical Products Administration (the “NMPA”). The Company has also been actively advancing the full-life-cycle management plans of drugs. Total expenditures incurred by the Company in 2021 was approximately RMB327.2 million, of which approximately RMB186.8 million was research and development expenses. As of December 31, 2021, the Company’s cash position was approximately RMB675.2 million.

Hua Medicine has consistently focused on unmet clinical needs. After 10 years of breakthrough exploration, from the scientific theory of glucose homeostasis regulation to an innovative drug with a new and novel mechanism, the Company has successfully developed dorzagliatin, a first-in-class innovative glucokinase activator for Type 2 Diabetes. In recent years, with the theoretical support of glucose homeostasis regulation, the research and development of new drugs for the treatment of diabetes and its complications has gradually increased. Relying on the scientific thesis of “repairing sensors, reshaping homeostasis and fundamentally treating diabetes”, dorzagliatin is expected to become a first-in-class innovative drug to be marketed first in China.

In addition, dorzagliatin has also demonstrated the potential of oral drug in diabetes remission in a clinical study. Based on the results of the DREAM study published in September 2021, dorzagliatin achieved a 52-week diabetes remission rate of 65.2% at week 52, without any glucose-lowering medication after the completion of the SEED study with early glycemic control. By achieving diabetes remission in the early stage of diabetes patients, dorzagliatin is expected to control or delay the occurrence and development of diabetes complications, offering feasible solutions to the medical burden and related social problems caused by diabetes.

At present, the NDA for dorzagliatin is under active review by the NMPA and Hua Medicine is actively working to obtain the approval of dorzagliatin as soon as possible. The Company will continue to strengthen its cooperation with Bayer, a leading Chinese diabetes and global healthcare enterprise. At the same time, it will work with WuXi AppTec, Sinopharm Group Co., Ltd., Desano, Raybow Pharmaceutical and other production and supply chain partners to jointly promote the stable production, sufficient supply and marketing of dorzagliatin. The Company will also seek opportunities to continue to expand the development opportunities of dorzagliatin in the European, American and Japanese markets, Southeast Asian market and the “Belt and Road” market to realize the value of innovation. In the future, the Company will explore the establishment of a management platform of chronic diseases, conduct scientific management of patients through big data, artificial intelligence and other means, and open up new prospects of chronic diseases.

Dr. Li CHEN, the founder, CEO and Chief Scientific Officer of Hua Medicine, said, “2021 was a breakthrough year for Hua Medicine. The Company’s core product, dorzagliatin, became the first glucokinase activator diabetes treatment drug to submit a new drug application in the world. Dorzagliatin is a drug with new concept, new mechanism, new efficacy, new structure and new technology, and is expected to achieve effective control and outcome of diabetes through the new concept of diabetes management of ‘fundamental treatment + peripheral treatment’. We look forward to the NDA approval regarding dorzagliatin as soon as possible, so as to benefit the patients with Type 2 Diabetes. Hua Medicine will continue to explore the health and development of the Chinese people, support the national strategy on the prevention and control of major diseases such as diabetes set out in the ‘Healthy China 2030’ initiative and realize the personalized treatment of diabetes.”

Clinical Research Progress
— In March 2021, we submitted a new drug application (“NDA”) for dorzagliatin for the treatment of Type 2 diabetes (“T2D”) to the National Medical Products Administration of the People’s Republic of China (the “NMPA”), and we received notification from the NMPA that our NDA was accepted in April 2021. The NDA is currently under active review by the NMPA.
— In September 2021 at the 6th China BioMed Innovation and Investment Conference, principal investigators of the DREAM study presented the extensive results from the clinical study. The main objective of the DREAM study was to evaluate the ability of T2D patients who participated in our SEED Trial and achieved glycemic control as defined by investigators, to maintain normal to near-normal HbA1c levels (i.e., remission of T2D), without any glucose-lowering medication after the completion of the SEED Trial for a minimum follow-up period of 52-weeks. The results showed that the subjects had a 52-week diabetes remission rate of 65.2% at week 52 (applying the Kaplan-Maier methodology) during the research period.
— We presented data from our 52-week SEED and DAWN Phase III registration trials, as well as Phase I trial HMM0112 of dorzagliatin in combination with empagliflozin (a SGLT-2 inhibitor) at the 2021 American Diabetes Association’s Scientific Sessions, demonstrating glucose control benefit using the combination of dorzagliatin and empagliflozin.
— We presented additional data from our Phase I trial HMM0111 of dorzagliatin in combination with Sitagliptin (a DPP-IV inhibitor) at the 2021 American Diabetes Association’s Scientific Sessions, demonstrating that dorzagliatin regulates GLP-1 secretion and has a synergistic effect on blood glucose control in patients with T2D in the United States.

Company Operation Progress
— In anticipation of dorzagliatin commercialization, we continue to work with Bayer, our commercialization partner in China, on launch strategy and commercialization preparation.
— In September 2021, we entered into a strategic agreement with Sinopharm Group Co., Ltd. (Hong Kong Stock Code: 1099), to cooperate in logistics warehousing, supply chain management and channel data analysis, and to jointly promote the commercialization of dorzagliatin for its anticipated market launch in China.
— In October 2021, we enhanced our existing collaboration with WuXi STA for the commercial supply of dorzagliatin by entering into an expanded agreement with WuXi STA, and for which we held a signing ceremony and announced the agreement in February 2022.
— We established Hua Medicine drug manufacturing company at Shanghai Lingang Special Area for ensuring adequate dorzagliatin commercial supply, and we also secured land for the construction of a manufacturing facility.
— We continue to make filings and applications regarding IP rights globally around our discoveries in glucokinase, including for fixed dose combinations with dorzagliatin, as well as a second generation glucokinase activator.

Financial Highlights
For the year ended December 31,2021
— Cash position was approximately RMB675.2 million.
— Total expenditures incurred by the Company was approximately RMB327.2 million, of which approximately RMB186.8 million was research and development expenses, representing a decrease of approximately RMB34.1 million or approximately 15%).
— Loss before tax decreased by approximately RMB67.4 million or approximately 17% to approximately RMB325.7 million.
— Loss and total comprehensive expense for the year decreased by approximately RMB68.3 million or approximately 17% to approximately RMB325.3 million.

Business Outlook
— We are working with the NMPA in obtaining approval for our NDA for dorzagliatin. If approved, we plan to commercialize dorzagliatin in China with our partner, Bayer, to seek entry into the National Reimbursement Drug List (the “NRDL”), and to expand its use as a cornerstone treatment for T2D as monotherapy or in combination with other approved antidiabetic drugs.
— We are planning to publicize the results of our SENSITIZE Trial in 2022.
— We are planning to initiate clinical trials in the United States for Type 1 diabetes with dorzagliatin.
— We are also advancing development of our fixed dose combinations with dorzagliatin, as well as our second generation glucokinase activator.

About Dorzagliatin
Dorzagliatin is an investigational first-in-class, dual-acting glucokinase activator, designed to control the progressive, degenerative nature of diabetes by restoring glucose homeostasis in patients with Type 2 diabetes. By addressing the defect of the glucose sensor function of glucokinase, dorzagliatin has the potential to restore the impaired insulin and GLP-1 secretion of patients with Type 2 diabetes and serve as a cornerstone therapy targeting the root cause of the disease. Two Phase III registration trials for dorzagliatin monotherapy and the combination of dorzagliatin and metformin have been completed in China, as well as studies on drug mechanism synergy with sitagliptin (DPP-4 inhibitor) and empagliflozin (SGLT-2 inhibitor). In an investigator-initiated study following the monotherapy Phase III SEED Trial, the DREAM Study, a 65.2% diabetes remission rate was observed at week 52 without any antidiabetes medication during the 52-week research period. The Company has obtained the “Drug Manufacturing Permit” of dorzagliatin issued by the Shanghai Municipal Drug Administrative Bureau, and has submitted its NDA to the National Medical Products Administration, so as to realize the “First in Global, Start from China” mission objective for the benefit of diabetic patients worldwide.

About Hua Medicine
Hua Medicine is an innovative drug development company in China focused on developing novel therapies for patients worldwide with unmet medical needs. Hua Medicine teams up with global high caliber people and integrates global resources to explore breakthrough technologies and products, and accelerate global innovation in diabetes care. Targeting the glucose sensor glucokinase, dorzagliatin, a novel oral diabetes drug, restoring glucose sensitivity in T2D patients, has completed SEED and DAWN registration trials, and filed NDA in China. This global first-in-class glucokinase activator (GKA) has demonstrated its potential of achieving diabetes remission to help millions of diabetic patients around the world.






Topic: Press release summary

Sectors: BioTech, Healthcare & Pharm


http://www.acnnewswire.com

From the Asia Corporate News Network

Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.








Old Crow Medicine Show and the Infamous Stringdusters to Headline 2nd Holla Yella Music Festival

 Holla Yella Music Festival returns for the 2nd consecutive year and will be held in the foothills of the Blue Ridge Mountains in the historic town of Ellijay. This year’s event will take place over the weekend of June 10-12, 2022. The festival will be a multi-day event and will host a diverse line-up of national and regional music acts in the genres of Bluegrass, Rock, Americana, Indie, Blues, Jam Band and Roots.

Festival headliners Old Crow Medicine Show and The Infamous Stringdusters will lead a stellar line-up of musical acts including Sierra Ferrell, Sierra Hull, Lera Lynn, Strung Like A Horse, Texas Hill, Fletcher’s Grove, Joslyn & the Sweet Compression, Surrender Hill, Jess Goggans Band, Eddie 9V, Ain’t Sisters, Mystery Cassette and Nero Simon & the Sunsetters. Legendary sensation Saxsquatch will emerge from the woods once again to host a late-night dance party on the opening night of the festival.

“We couldn’t be happier to announce this year’s amazing line-up, from our established headliners Old Crow Medicine Show and The Infamous Stringdusters, to our first-rate artists like Sierra Ferrell, Lera Lynn, Sierra Hull, and of course the phenomenal Saxsquatch,” said Nero Simon, Georgia-based singer-songwriter and festival co-founder. “The talent and quality on our main and pavilion stages will help our goal of making Holla Yella one of the premiere annual music festivals in the state of Georgia.”

In addition to these and other musical artists, the festival will also feature aerialists, hula hoop and fire performers along with a diverse assortment of food trucks and arts and crafts vendors. Cathead Vodka will return for the 2nd year as a festival sponsor along with local food & drink establishments Ellijay Woodfired Pizza and Kasei Sushi & Sake as well as the Gilmer County Chamber of Commerce.

Where: White Path Creek Farms, Ellijay, GA

When: Friday, June 10, 2022 – Main and Pavilion stages

Saturday, June 11, 2022 – Main and Pavilion stages

Sunday, June 12, 2022 – Caribbean Brunch in the Pavilion with Nero Simon & the Sunsetters

Tickets and more information can be found at www.hollayella.com.

About Holla Yella Music Festival

Co-founded in 2021 by Ellijay-based restaurateurs Marcelo and Candace Sandrini and singer-songwriter Nero Simon, Holla Yella Music Festival is held in the foothills of the Blue Ridge Mountains in the historic town of Ellijay, Georgia. The festival aims to become one of Georgia’s leading music and arts festivals. This celebration brings together music artists from genres including rock, americana, bluegrass and jam bands for an amazing weekend of fun in the sun in the Appalachian mountains.

Media inquiries:

info@hollayella.com

(678) 438-9341

Holla Yella LLC

Jodi Ramsey

706-266-6660

www.hollayella.com

ContactContact

Categories

  • Arts & Entertainment
  • Events & Concerts
  • Music
  • Performing Arts

Canada – Patented Medicine Prices Review Board seeks applicants for Chairperson position

Ottawa, ON — Patented Medicine Prices Review Board

The Government of Canada is seeking applicants for the Chairperson position on the Patented Medicine Prices Review Board by way of an open, transparent, and merit-based Governor in Council selection process.

Members of the Board are part-time, Governor in Council appointees who preside over hearings into allegations of excessive drug pricing brought by PMPRB staff against patent-holding pharmaceutical companies.

The Chairperson exercises direction, as Chief Executive Officer, over the quasi-judicial and operational functions of the PMPRB and exercises authority as Deputy Head under the Financial Administration Act.

Candidates interested in this unique opportunity are encouraged to apply online by visiting Canada.ca for more information.

Enhancing Military Medicine in an Era of Great Power Competition at Defense Strategies Institute’s 3rd Annual Operational Medicine Symposium

 Defense Strategies Institute is proud to announce the 3rd annual Operational Medicine Symposium, taking place September 29-30, 2021 in San Antonio, TX. This year’s Symposium will highlight recent advancements in battlefield medicine, including in areas of combat casualty care, medical logistics, human performance and telemedicine, which expand the survivability of our Nation’s warfighters, highlighting this year’s theme “Advancing Battlefield Medical Capabilities to Improve Warfighter Survivability.”

The nature of operational medicine and the US military health system is at an inflexion point. The DoD is preparing for a medical operating environment which will be characterized by great power competition, high casualties, denied evacuation routes and advanced weaponry. Speakers at this senior level forum will share their perspectives on innovating and partnering with industry providers to deliver cutting-edge medical equipment to warfighters to ensure we are able to reliably care for warfighters at the point of need.

The 2021 Operational Medicine Symposium will feature senior-level speakers including:

– MG Dennis LeMaster, USA, Commanding General, US Army Medical Center of Excellence

– Brig Gen Paul Friedrichs, USAF, Joint Staff Surgeon, Joint Chiefs of Staff

– Brig Gen Thomas Harrell, USAF, Commander, Air Force Medical Readiness Agency

– Col Stacy Shackelford, USAF, Chief, Joint Trauma System

– Col Caesar Junker, USAF, AI Leader, Human Performance Health Mission Director, Joint Artificial Intelligence Center

– MAJ Garret Larson, USA, Deputy Director of Operations, Virtual Medical Center

Topics to be covered at the Symposium Include:

– Leveraging Holistic Health and Fitness to Prepare Soldier for Multi-Domain Operations

– Preparing the Medical Force for the Future Operating Environment Developing effective countermeasures against stressors in order to maximize health, performance, and well-being

– Injury Prevention and Reduction

– USINDOPACOM Requirements from the Medical Community to Improve Performance and Ensure the Health and Readiness of the Joint Force

– Preparing the Medical Force for Large Scale, Multi-Domain Operations

– Advancements in Telehealth to Improve Patient Outcomes

– And more.

DSI is now welcoming Sponsors and Exhibitors for the forum. Reserve your spot to showcase your organizations cutting-edge technologies to over 250 attendees from all services, medical units, industry partners and practitioners. To learn more please contact Thomas Engelman at tengelman@dsigroup.org, 201-918-3477.

Current Sponsors & Exhibitors Include: Leidod, MedWeb, AcelRX, DripDrop, Fort Defiance Industries and Zoll.

In order to allow for actionable discussion and dialogue amongst speaker and attendees, seating will be limited. Register now to reserve your seat. Active military and government and state personnel attend complimentary. Those interested in participating in the 3rd Operational Medicine Symposium can visit Defense Strategies Institute’s website at http://operationalmedicine.dsigroup.org/.

Anyone interested in learning more or sending questions contact Erica Noreika at enoreika@dsigroup.org, 201-896-7802.

Defense Strategies Institute

Erica Noreika

201-896-7802

https://operationalmedicine.dsigroup.org/

ContactContact

Categories

  • Government